1. Home
  2. SMID vs PYXS Comparison

SMID vs PYXS Comparison

Compare SMID & PYXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Smith-Midland Corporation

SMID

Smith-Midland Corporation

HOLD

Current Price

$29.40

Market Cap

157.6M

Sector

Industrials

ML Signal

HOLD

Logo Pyxis Oncology Inc.

PYXS

Pyxis Oncology Inc.

HOLD

Current Price

$3.06

Market Cap

166.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SMID
PYXS
Founded
1960
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Building Materials
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
157.6M
166.6M
IPO Year
1996
2021

Fundamental Metrics

Financial Performance
Metric
SMID
PYXS
Price
$29.40
$3.06
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$7.00
AVG Volume (30 Days)
13.3K
1.1M
Earning Date
04-14-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
62.76
3.03
EPS
0.25
N/A
Revenue
$93,446,000.00
$13,858,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$7,043.98
P/E Ratio
$118.16
N/A
Revenue Growth
19.03
N/A
52 Week Low
$25.60
$0.97
52 Week High
$43.62
$5.55

Technical Indicators

Market Signals
Indicator
SMID
PYXS
Relative Strength Index (RSI) 48.78 68.95
Support Level $26.74 $1.37
Resistance Level $36.74 $3.89
Average True Range (ATR) 1.49 0.38
MACD 0.08 0.08
Stochastic Oscillator 44.35 80.13

Price Performance

Historical Comparison
SMID
PYXS

About SMID Smith-Midland Corporation

Smith-Midland Corp through its subsidiaries invents, develops, manufactures, markets, sells, and installs precast concrete products for primary use in the construction, highway, utilities, and farming industries. The firm's customers are general contractors and federal, state, and local transportation authorities. Its products include Slenderwall, JJhooks, Softsound, Sierra Wall and Easi set. A substantial portion of the company's business is derived from local, state, and federal building projects. The company generates revenues predominantly from the sale, leasing, licensing, shipping, and installation of precast concrete products for the construction, utility, and farming industries.

About PYXS Pyxis Oncology Inc.

Pyxis Oncology Inc is a clinical-stage oncology company focused on developing therapies for patients with solid tumors, with an initial emphasis on head and neck squamous cell carcinoma. Its product candidate, micvotabart pelidotin (MICVO, formerly PYX-201), is an investigational antibody-drug conjugate that targets extradomain-B fibronectin (EDB+FN), a component of the tumor extracellular matrix that is expressed in tumors and minimally present in normal tissues. MICVO consists of a fully human monoclonal antibody linked to a microtubule inhibitor payload, designed to bind within the tumor microenvironment and release its payload to kill cancer cells directly, affect nearby cells through a bystander effect, and induce immunogenic cell death, supporting enhanced anti-tumor activity.

Share on Social Networks: